Goserelin EP Impurity C is a related peptide that forms during goserelin synthesis or storage. Differences in residue modification or deprotection steps shift hydrophobicity and conformational properties. Researchers analyze it to refine impurity profiles and assess method accuracy. Applications include stability testing, synthetic-route comparison, and structure-impurity correlation.
CAT No: Z10-101-234
Synonyms/Alias:[9-D-Proline]goserelin; (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((R)-2-(2-carbamoylhydrazinecarbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide
Goserelin EP Impurity C is a synthetic peptide derivative recognized as a process-related impurity associated with the manufacture of goserelin, a well-established gonadotropin-releasing hormone (GnRH) agonist. Structurally, it shares significant homology with the parent peptide, making it a critical reference standard and analytical tool in peptide chemistry and pharmaceutical quality control. The presence and quantification of such impurities are essential for ensuring the fidelity, safety, and efficacy of peptide-based therapeutics, as minor sequence variations can impact both biological activity and stability. As a chemically defined entity, Goserelin EP Impurity C supports a range of applications in analytical development, regulatory compliance, and peptide characterization studies.
Analytical method development: In pharmaceutical research and manufacturing, the use of process impurities like Goserelin EP Impurity C is fundamental for developing and validating robust analytical methods. High-performance liquid chromatography (HPLC), mass spectrometry, and related techniques require well-characterized impurity standards to accurately detect, separate, and quantify trace-level contaminants in peptide drug substances. The availability of this impurity enables analysts to optimize method sensitivity and specificity, ensuring that the main product and its related substances are reliably distinguished during quality assessment.
Quality control and batch release: Routine quality control protocols for peptide active pharmaceutical ingredients (APIs) rely on the detection and quantification of known impurities to verify batch consistency and compliance with regulatory specifications. Goserelin EP Impurity C serves as a reference material in these workflows, allowing laboratories to monitor impurity profiles across production lots. Its use supports the establishment of impurity thresholds, facilitates root cause analysis in the event of deviations, and underpins the documentation required for product release.
Peptide degradation studies: The structural similarity of this impurity to goserelin makes it an ideal probe for forced degradation and stability-indicating studies. Researchers utilize Goserelin EP Impurity C to simulate and characterize potential degradation pathways that may occur during storage, formulation, or handling of peptide drugs. By tracking the formation and behavior of such impurities under stress conditions, scientists gain valuable insights into the mechanisms of peptide instability and can devise strategies to enhance product shelf life.
Process optimization and impurity profiling: In peptide synthesis, the formation of specific impurities can inform process optimization efforts aimed at improving yield and purity. The identification and quantification of Goserelin EP Impurity C provide process chemists with actionable data to refine reaction conditions, purification protocols, and overall manufacturing strategies. Understanding the origin and fate of this impurity enables targeted adjustments that minimize its formation, contributing to more efficient and reproducible peptide production.
Pharmacopoeial and regulatory compliance: The European Pharmacopoeia and other regulatory authorities require thorough characterization and control of process-related impurities in peptide pharmaceuticals. Goserelin EP Impurity C is used as a compendial reference standard to demonstrate compliance with monograph requirements and to support regulatory submissions. Its inclusion in analytical assessments ensures that impurity levels are within acceptable limits, thereby safeguarding product quality and facilitating market authorization for peptide-based drug products.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More